Our evaluation of the cost-effectiveness of CDK4/6 inhibitors in combination with letrozole as a first-line treatment for HR+/HER2- advanced breast cancer provided valuable insights into the economic and clinical considerations of these therapeutic strategies. This evidence concerns the gene CDK4 and breast cancer.